In this Cancer Matters podcast, Dr Bill Nelson talks to Dr Ken Kinzler, cancer researcher and Co-Director of Ludwig Cancer Research at Johns Hopkins, about… Read More »Cancer Matters with Dr. Bill Nelson – Cancer Genetics
In the next podcast reviewing the 50th Anniversary of the Johns Hopkins Kimmel Cancer Center, Dr Bill Nelson and Dr Otis Brawley analyze the successes… Read More »50th Anniversary of the Kimmel Cancer Center – Cancer Mortality
Each year, the American Cancer Society publishes data that gives a review of cancer statistics with foundational data that tells us about new cases in… Read More »Great News for Lung Cancer Patients
In this Cancer Matters podcast, Dr Bill Nelson talks with Dr Julie Brahmer about the advances made in treating patients with lung cancer, smoking cessation… Read More »Cancer Matters with Dr. Bill Nelson – Advances in Lung Cancer
In the next Cancer Disparities podcast, Dr Otis Brawley says that while #cancer screening is very important, focusing on prevention and ensuring adequate access to treatment for… Read More »Cancer Disparities with Dr. Otis Brawley – Screening, Prevention and Treatment
--This post was written by lung cancer expert Dr. Phillip Dennis. Lung cancer is the most deadly cancer in the United States and will kill… Read More »Lung cancer screening recommendations
Prostate cancer topics abound in the latest Cancer News Review podcast. Dr. Bill Nelson, director of the Johns Hopkins Kimmel Cancer Center, discusses Hopkins-led research, published in… Read More »Cancer News Review
Recent news of the full results of the National Lung Screening Trial (NLST) published in the New England Journal of Medicine underscores the heavy toll… Read More »Lung Cancer: Still the Top Cancer Killer
Starting in 2002, more than 50,000 current and former smokers aged 55 to 74 signed up for the National Lung Screening Trial (NLST) at Johns Hopkins and more than 30 other sites across the nation. The trial was to last 10 years, but eight years into the study, leaders of the trial found their results thus far were significant enough to stop the trial and announce their findings.